Background: Perinatal asphyxia is a major cause of mortality and morbidity in neonates: The aim of the present study was to investigate, by means of longitudinal assessment of urinary S100B, the effectiveness of hypothermia, in infants complicated by perinatal asphyxia and hypoxicischemic encephalopathy. Methods: We performed a retrospective case-control study in 108 asphyxiated infants, admitted to nine tertiary departments for neonatal intensive care from January 2004 to July 2017, of whom 54 underwent hypothermia treatment and 54 did not. The concentrations of S100B
Introduction
Perinatal asphyxia (PA) and its complication, hypoxic ischemic encephalopathy (HIE), constitute a well-known cause of major injury of the central nervous system (CNS) characterized by a pattern of hypoxia, acidemia and multi-organ failure [1] . Short-and/or long-term CNS injuries, including developmental delay, intellectual disability and/or spasticity, are present in up to 25%-28% of PA term infants [2, 3] . PA biochemical pattern includes: (i) in the early phase, massive cell death due to primary exhaustion of cellular energy stores [4] , (ii) within several hours, neuronal injury caused by oxygen free radicals, intracellular calcium entry, and apoptosis [5] , and (iii) the so-called third phase, which may last for weeks and more, characterized by a persistent brain injury mediated by gliosis and by an exaggerated inflammatory response leading to epigenetic changes [6] . In this dramatic scenario, neonatologists can resort to standard monitoring procedures (i.e. blood pH; measurement of uric acid and lactate; cerebral ultrasound, CUS; continuous electroencephalogram recordings, aEEG), although in the early post PA period brain injury may be at a sub-clinical stage and its symptoms hidden by the effects of the therapeutic strategies performed [7] [8] [9] [10] . Currently, selective/total body hypothermia (HT) is considered the standard procedure for PA [11] [12] [13] [14] . However, HT is effective only in mild-moderate HIE, whilst no positive or conclusive results have been shown for severe HIE [11] . Monitoring of the CNS during HT has not been optimized as magnetic resonance imaging (MRI), considered the gold standard to predict neonatal outcome, has limited value in the first hours after birth [15] , partly due to infrastructure limitations and neonatal critical conditions. Thus, measurement of quantitative parameters able to diagnose sub-clinical lesions at an early stage and to evaluate the effectiveness of the therapeutic strategies performed could be especially useful. S100B protein is an acidic calcium-binding protein located mainly in glial cells and in neuronal subpopulations of the CNS [16] [17] [18] [19] [20] [21] [22] [23] and mostly eliminated by the kidneys [24] . Among the different biological fluids, available for S100B monitoring, repeated urine sampling is easy and without risks for the newborn. In the perinatal period, elevated S100B levels in different biological fluids have been associated with CNS damage monitored through the use of CUS and MRI patterns, as well as short-/long-term follow-up [17] [18] [19] [20] . S100B has also been used to monitor the effectiveness on the CNS of perinatal therapeutic strategies such as nitric oxide donors, glucocorticoids and antidepressant drugs [25] [26] [27] . To date, data on the effectiveness and timing at which HT begins to be neuroprotective are still lacking. Therefore, the purpose of the Cooperative Multitask against Brain Injury of Newborns (CoMBINe) was to investigate HT effectiveness in the first hours of treatment by means of longitudinal S100B monitoring in urine.
Materials and methods
The Local Ethics Committees of the CoMBINe International study (Alessandria, Modena, Rome, Italy; Warsaw, Poland; Cairo, Egypt) approved the study protocol and informed and signed consent was obtained from all parents of patients.
We conducted a retrospective case control study in 120 PA infants admitted to our third level referral centers for neonatal intensive care units (NICUs) between January 2004 and July 2017.
For sample size calculation, we used changes in S100B urine concentrations in PA infants at 72 h as the main parameter [28] . As no basic data are available regarding HT-treated PA populations, we assumed a decrease of 0.5 SD in S100B to be clinically significant. Considering an α = 0.05 and using a two-sided test, we estimated a power of 0.95, recruiting 50 HT-treated PA infants and 50 controls. We added n = 10 per group to allow for dropouts, crossover and mortality.
The study population was therefore composed of 54 PA infants who underwent HT (HT-group), matched for gestational age (GA) and birth weight (BW) with 54 PA infants who did not receive HT treatment (noHT-group). In accordance with Sarnat's criteria [29] , the HT-and noHT-groups were then subdivided into PA infants with moderate HIE (HTm: n = 27; noHTm: n = 27) and severe HIE (HTs: n = 27; noHTs: n = 27) ( Figure 1 ).
All asphyxiated infants were delivered by emergency cesarean section because of acute fetal distress classified according to the criteria of the American College of Obstetricians and Gynecologists [30] . Asphyxia was defined as Apgar score <3 at 5 min, pH < 7.0, base excess ≤ −12 mmol/L in cord or venous blood taken within 60 min of birth, the need for resuscitation at birth and/or for positive pressure ventilation (>3 min), and the occurrence of multiorgan failure [30] . Infants fulfilling three or more of the above criteria were included in the asphyxia group, received mechanical ventilation, and were sedated by means of fentanyl citrate (Fentanest; Pharmacia & Upjohn International, Milan, Italy), 0.5-2.5 μg/kg per h, and midazolam hydrochloride (Ipnovel; Roche SA, Fontenay-sous-Bois, France), 50-400 μg/kg per h. Exclusion criteria were: CNS malformations, chromosomal abnormalities, congenital heart diseases, multiple pregnancies, congenital infections, maternal drug addiction, hypertension and diabetes. Infants with any malformation, intrauterine growth retardation, cardiac or hemolytic disease were also excluded from the study.
Clinical and laboratory parameters (red blood cell count, RBC; hemoglobin blood concentrations, Hb; hematocrit rate, Ht; venous blood pH; partial carbon dioxide venous pressure, PCO 2 ; partial oxygen venous pressure, PO 2 ; base excess, BE; blood ion, glucose, urea, and creatinine levels) were recorded in all infants on admission to NICUs and at 24 h, 72 h and 120 h from birth. CUS and neurological patterns were assessed by a single examiner in each center, blinded to the urine test results. 
HT management
In the HT-group passive cooling was initiated immediately after diagnosis of PA, and active HT started always within 6 h from birth. During HT, the PaCO 2 target range was 45-60 mmHg. The cooling system was a total-body, servo-controlled, water-circulated device (Tecotherm iCool, Inspiration Healthcare Group, Crawley, UK), programmed to maintain a rectal temperature of 33.5 °C for 72-h [11, 31] .
Rewarming was performed at a rate of ≤0.5 °C per h, up to a rectal temperature of 37.0 °C. Hypotension was treated if mean blood pressure was persistently <40 mmHg for >20 min.
Cerebral function monitoring (CFM)
CFM recordings were monitored already before the beginning of active cooling, throughout the entire HT procedure, and until 72 h after rewarming by using a dedicated device (CFM Olympic Brainz Monitor, Natus Medical Incorporated, CA, USA). EEG stick-on electrodes (Denis, Spes Medica, Genoa, Italy) were applied to neonatal scalps and used in a reduced montage according to the International 10/20 system [32] . A single channel cross-brain aEEG trace (from central electrodes C3-P3) was derived in order to assess aEEG background pattern classification. This single channel also recorded EEG. An evaluation of the aEEG background voltage and pattern was performed every hour from monitoring beginning until 72 h after rewarming. aEEG recordings were defined as continuous or discontinuous normal voltage, burst suppression, low voltage or flat trace. The occurrence of electrographic seizures (repetitive, stereotyped waveforms with definite onset, peak and end, of 10 s or longer of raw EEG) or status epilepticus (continuous/repetitive ictal activity ≥30 min) was assessed [8] . The examiner who reviewed aEEG results was blinded to the newborns' clinical course.
Cranial assessment
CUS recordings were performed by real-time ultrasound machine (Acuson 128SP5, Mountain View, CA, USA), at 12 h and 24 h from admission and on discharge from the hospital. In the controls, CUS patterns were evaluated before discharge from the hospital.
Neurological examination
Neonatal neurological conditions were assessed daily and classified as described by Prechtl [33, 34] . Each infant was defined as normal, suspect or abnormal, in accordance with the classification used by Jurgens-van der Zee et al. [35] . Infants were considered abnormal when one or more of the following neurological symptoms were unequivocally present: (i) increased/decreased excitability (hyperexcitability syndrome/convulsions/apathy syndrome/coma), (ii) increased/decreased motility (hyperkinesia/hypokinesia), (iii) increased/decreased tonus (hypertonia/hypotonia), (iv) asymmetries (peripheral/central), (v) CNS defects and (vi) any combination of the above. When indications of the presence of a symptom were inconclusive or if only isolated symptoms were present, i.e. mild hypotonia or only a slight tremor, the case was classified as suspect.
The presence within the first 7 days of life of HIE was classified according to Sarnat and Sarnat [29] . HIE was defined as "mild" if hyperexcitability or hypotonia persisted without seizures for at least 72 h after birth; "moderate" if the infant was lethargic and had hypotonia, weak primitive reflexes and seizures; and "severe" if the infant suffered frequent seizures, apnea, flaccid weakness or coma.
S100B measurement
Urine samples (100 μL) were collected by a standard urine collector (Pennine Heathcare, London, UK) and measured at first void (time 0, T0), 4 (time 1, T1), 8 (time 2, T2), 12 (time 3, T3), 16 (time 4, T4), 20 (time 5, T5), 24 (time 6, T6), 36 (time 7, T7), 48 (time 8, T8), 72 (time 9, T9), 96 (time 10, T10), 108 (time 11, T11) and 120 (time 12, T12) h from birth. In the asphyxiated infants, a catheter was inserted into the bladder for urine sampling because of their critical clinical conditions and the effects of sedative drugs. The studied groups included only infants in whom urination occurred at least 10 times during the collection times. After collection, urine samples were immediately centrifuged at 900 g for 10 min and stored at −70 °C until the assay. S100B levels were measured using an immunoluminometric assay (Liaison S100, Dietzenbach, Germany) according to the manufacturer's instructions. The detection limit of the assay was 0.02 μg/L, the coefficient of variation was ≤3.9% within-assay and ≤6.2% interassay for concentrations ranging between 0.12 and 17.5 μg/L.
Statistical analysis
When the Kolmogorov-Smirnov test showed that values were not normally distributed, S100B concentrations were expressed as medians and interquartile ranges and statistical significance of differences evaluated using a non-parametric test. Data on neonatal outcomes and laboratory parameters were analyzed according to Tukey's oneway ANOVA and the two-sided Mann-Whitney U-test. Comparison between proportions was performed using Fisher's exact test. Statistical significance was set at p < 0.05. Table 1 shows perinatal characteristics of the studied groups corrected for the occurrence of moderate/severe HIE. No significant differences (p > 0.05) were observed in the groups regarding BW, GA, gender, cesarean section incidence, Apgar scores at 1 and 5 min, incidence of respiratory distress syndrome, and need for mechanical ventilation and inotropic therapy. No significant differences (p > 0.05) were observed between groups regarding aEEG, Sarnat score and neurological examination. Nor were any differences (p > 0.05) found in the interval before cooling was initiated.
Results
No significant differences (p > 0.05) among groups were found at birth in RBC, Hb, Ht, pH, venous pCO 2 , pO 2 , BE, blood ion, glucose, urea and creatinine levels ( Table 2) . S100B protein in the HTm-and HTs-groups S100B protein was measurable in all samples collected. In the HTm-group from the first void (T0) onwards protein levels significantly increased (p < 0.05), peaking at T1 (4-h), when they started to decrease at monitoring time-points T2-T12 (8-120-h) reaching their trough at T9 (72-h) (Figure 2 ). In the HTs-group, from the first void (T0) onwards protein levels significantly increased (p < 0.05), peaking at T4 (16-h), when they started to decrease at monitoring time-points T5-T10 (20-120-h) reaching their trough at T11 (108-h) and remaining within normal ranges at T12 (120-h) (Figure 2 ). When S100B concentrations in the severe and moderate HTgroups were compared at different monitoring timepoints, we detected significantly (p < 0.001) elevated Table 2 : Laboratory parameters recorded at birth in perinatal asphyxia infants complicated by mild-moderate (m) or severe (s) hypoxicischemic encephalopathy treated (HT) or not (noHT) by total body hypothermia.
HTm (n = 27)
HTs (n = 27) noHTm (n = 27) noHTs (n = 27) Values are expressed as mean ± SD. RBC, red blood cell count; Hb, hemoglobin; Ht, hematocrit rate; pCO 2 , partial carbon dioxide venous pressure; pO 2 , partial oxygen venous pressure; BE, base excess. concentrations of S100B in the HTs-group up to T6 (24-h), whereas from T7-T12 (36-120-h) no significant differences were found ( Figure 2 ).
S100B protein in the noHTm-and noHTs-groups
S100B protein was measurable in all samples collected. In both the noHTm-and noHTs-groups S100B significantly (p < 0.001) increased from the first void (T0) onwards, peaking at T11 (108 h) and remaining higher at T12 (120 h) ( Figure 3) . When S100B at different monitoring time-points was compared between noHT-groups, we found significantly (p < 0.001) higher concentrations of the protein in the noHTs-group at all monitoring time-points (Figure 3 ).
HTm vs. noHTm
No significant differences (p > 0.05) in S100B levels were found at first void (T0), T4 (16 h) or T11-12 (108-120 h). Elevated (p < 0.001) S100B levels were observed in the HTm-group from T1 to T3 (4-12 h), whilst in the noHTmgroup a significant (p < 0.01) increase in S100B from T6 to T9 (24-72 h) was found ( Figure 4 ).
HTs vs. noHTs
At first void (T0) S100B did not differ (p > 0.05) between these groups, whilst from T1 to T6 (4-24 h) higher S100B levels (p < 0.001) were found in the HTs-group. From T7 onwards (36-120 h) S100B levels were significantly (p < 0.01) higher in the noHTs-group ( Figure 5 ).
Discussion
Perinatal asphyxia is a severe complication potentially leading to HIE and/or death [36] . As well as posing the highest risk for adverse short-/long-term neurological outcomes, PA and HIE also represent a dramatic psychological and financial burden on families and social welfare systems [37] . Thanks to technological developments, HT has been shown to improve neonatal outcomes in moderate HIE, though only poor results have been achieved in severe HIE [9] . In addition, no certain data exist yet about either the optimal time-window for the beginning of HT treatment or when HT starts to be effective. In this regard, the Food and Drug Administration and the European Medicine Association promoted the usefulness of neurobiomarkers to assess the efficacy of therapeutic strategies, especially in the perinatal period [38] .
In the present study we found that urine concentrations of the well-established biomarker S100B protein were significantly higher in both moderate (up to 12 h) and severe (up to 24 h) HT-treated HIE groups than in noHTtreated infants. Furthermore, beginning from 20 h of HT in moderate HIE, and from 36 h onwards in severe HIE forms, S100B levels significantly decreased to reach the normal ranges.
The pattern of increased S100B levels in urine is in agreement with previous reports in the blood of neonates undergoing HT [34] . The S100B levels detected in noHTtreated infants fit previous observations in different biological fluids (blood, urine, saliva) [16-19, 23, 39] . These findings are particularly relevant considering that no differences in the degree of HIE severity were shown among groups.
The S100B patterns in neonates with moderate HIE, whether or not treated with HT, deserve further consideration. In particular, S100B in HTm-treated infants was significantly higher up to 12-h, suggesting the presence of putative CNS stress/damage. Bearing in mind that clinical, laboratory and standard monitoring procedures were comparable between the groups, a possible explanation may reside in the HT procedure itself and, more specifically, in its cooling phase. A similar trend in part was described by Massaro et al. although discrepancies with our observations may be explained by different study design and monitoring time-points [40] . In addition, Alshweki et al. found longitudinal decreased S100B levels in blood and urine up to 3 days from hypoxic insult in PA HIE infants with good or poor outcome although higher protein's levels were observed in those with poor outcome [41] .
Nonetheless, similar S100B patterns were found in congenital heart disease (CHD) infants who underwent surgical procedure by cardiopulmonary by-pass (CBP) including a cooling phase of variable duration (<3 h) depending on CHD severity [42] [43] [44] . Thus, reminding that PA HIE infants were subjected to prolonged low temperature (72 h at 33.5 °C), the possibility that the higher S100B levels detected in the first 12 h in HTm-group could be temperature-dependent is consistent. It is possible to infer, in this regard, that a delayed metabolism typical of HT procedure could be at least partly responsible for these higher S100B levels. Other explanations may lie in: (i) transient changes in blood-brain barrier permeability occurring in the first phase of HT [45] , (ii) the infants' adaptation to the low temperature, and (iii) the starting point of HT effectiveness. This latter point is corroborated by stable S100B levels within normal ranges from 16 h onwards. Future investigations aimed at elucidating whether a 12 h cut-off could express the efficacy of HT or an unexpected possibility to enlarge the time-window suitable for HT treatment are eagerly awaited.
In the present study we also found that S100B levels in HTs infants were significantly increased in the first 36 h from the start of HT. The pattern is consistent with that previously described in HTm neonates, except for the entity and duration of protein release into urine. These findings warrant further consideration in addition to the above explanations in terms of: (i) exaggerated release of S100B as the expression of massive cytolysis occurring in HTs newborns, (ii) a longer time-window during which HT is ineffective, suggesting that the time required before the protective effects of HT are felt is proportional to the entity of brain damage, and (iii) a progressive increase in protein concentrations from 108 h onwards (at the conclusion of the rewarming phase), which might reflect the occurrence of the so-called third phase characterized by gliosis and an accentuated inflammatory response. Altogether, it is reasonable to suggest that the pattern of S100B levels in HTs infants offers additional support to the claim that HT is not effective in severe HIE [10] [11] [12] [13] [14] . The detection of a longer time-window in the first 24 h from treatment and of an unexpected increase from 108 h onwards suggests the usefulness of further studies aimed at investigating the criteria for timing patients' recruitment and the duration of HT. To the best of our knowledge, there is only a single report by Laptook et al. investigating the efficacy and safety of different timings of HT in PA infants [46] . Finally, the present study has limitations, principally those associated with the conduct of retrospective case control studies. However, at the moment, due to ethical medical issues and to the current international guidelines for the treatment of PA and HIE, it would be impossible to conduct a randomized study recruiting HT-treated vs untreated PA infants. Therefore, we decided to recruit from our database PA and HIE infants, suitable for HT treatment, at a time (from 2004 onwards) when the majority of the centers, participating to the CoMBINe network, did not perform HT due to infrastructure limitations.
Another limitation is linked to the different PA classification scores (Sarnat vs. Shankaran) in force at the times of patients' recruitment. Lastly, the possibility of a potential bias due to sample collection procedures at different centers has to be taken into account, although all participants in the study followed the same protocol and performed HT with the same strategy (total body cooling).
In conclusion, the present results offer additional support for the usefulness of neuro-biomarkers in CNS monitoring during HT treatment. The elevated S100B patterns of concentration described in the early and late phases of HT procedure may point the way to further studies aimed at clarifying S100B roles: biomarker of hypoxia, an early warning signal of brain damage occurrence or, last but not least, a marker for identifying the most appropriate time-window for patients' recruitment and the optimal duration of the cooling and rewarming phases of HT in PA infants.
